These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 31559852

  • 21. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A, Huerta A, Navarro Artieda R, Monsó E, Landis SH, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
    Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA.
    Respir Res; 2018 Nov 20; 19(1):224. PubMed ID: 30458866
    [Abstract] [Full Text] [Related]

  • 23. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials.
    Rabe KF, Chalmers JD, Miravitlles M, Kocks JWH, Tsiligianni I, de la Hoz A, Xue W, Singh D, Ferguson GT, Wedzicha J.
    Adv Ther; 2021 Jan 20; 38(1):579-593. PubMed ID: 33175291
    [Abstract] [Full Text] [Related]

  • 24. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.
    Pulm Pharmacol Ther; 2015 Jun 20; 32():53-9. PubMed ID: 25956072
    [Abstract] [Full Text] [Related]

  • 25. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study.
    Hoogendoorn M, Corro Ramos I, Soulard S, Cook J, Soini E, Paulsson E, Rutten-van Mölken M.
    BMJ Open; 2021 Aug 04; 11(8):e049675. PubMed ID: 34348953
    [Abstract] [Full Text] [Related]

  • 26. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
    Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Aug 04; 18():1431-1444. PubMed ID: 37465818
    [Abstract] [Full Text] [Related]

  • 27. The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects.
    Derom E, Brusselle GG, Joos GF.
    Ther Adv Respir Dis; 2019 Aug 04; 13():1753466619843426. PubMed ID: 31002020
    [Abstract] [Full Text] [Related]

  • 28. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA, Cates CJ.
    Cochrane Database Syst Rev; 2015 Oct 22; (10):CD008989. PubMed ID: 26490945
    [Abstract] [Full Text] [Related]

  • 29. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
    Buhl R, Magder S, Bothner U, Tetzlaff K, Voß F, Loaiza L, Vogelmeier CF, McGarvey L.
    Respir Med; 2017 Jan 22; 122():58-66. PubMed ID: 27993292
    [Abstract] [Full Text] [Related]

  • 30. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study.
    Dalon F, Roche N, Belhassen M, Nolin M, Pegliasco H, Deslée G, Housset B, Devillier P, Van Ganse E.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan 22; 14():1839-1854. PubMed ID: 31692478
    [Abstract] [Full Text] [Related]

  • 31. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.
    Ichinose M, Minakata Y, Motegi T, Ueki J, Gon Y, Seki T, Anzai T, Nakamura S, Hirata K.
    Int J Chron Obstruct Pulmon Dis; 2018 Jan 22; 13():1407-1419. PubMed ID: 29750027
    [Abstract] [Full Text] [Related]

  • 32. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
    Hahn B, Hull M, Blauer-Peterson C, Buikema AR, Ray R, Stanford RH.
    Respir Med; 2018 Jun 22; 139():65-71. PubMed ID: 29858004
    [Abstract] [Full Text] [Related]

  • 33. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS, DePietro M, McPheeters J, Fox KM.
    Ther Adv Respir Dis; 2018 Jun 22; 12():1753466618772750. PubMed ID: 29737943
    [Abstract] [Full Text] [Related]

  • 34. Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment.
    Capel M, Mareque M, Álvarez CJ, Lindner L, Oyagüez I.
    Clin Drug Investig; 2018 Jul 22; 38(7):611-620. PubMed ID: 29654555
    [Abstract] [Full Text] [Related]

  • 35. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
    Ferguson GT, Karpel J, Bennett N, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.
    NPJ Prim Care Respir Med; 2017 Feb 02; 27(1):7. PubMed ID: 28154373
    [Abstract] [Full Text] [Related]

  • 36. A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis.
    He J, Lin JT.
    Medicine (Baltimore); 2020 Apr 02; 99(16):e19789. PubMed ID: 32311990
    [Abstract] [Full Text] [Related]

  • 37. [Current position of new fixed-dose combination of tiotropium and olodaterol - its role in the treatment of chronic obstructive pulmonary disease in the Czech Republic].
    Koblížek V, Svoboda M.
    Vnitr Lek; 2016 Apr 02; 62(12):1011-1020. PubMed ID: 28139131
    [Abstract] [Full Text] [Related]

  • 38. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease.
    Chatterjee A, Shah M, D'Souza AO, Bechtel B, Crater G, Dalal AA.
    Respir Res; 2012 Feb 17; 13(1):15. PubMed ID: 22340019
    [Abstract] [Full Text] [Related]

  • 39. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
    Prescrire Int; 2016 Nov 17; 25(176):272-277. PubMed ID: 30715829
    [Abstract] [Full Text] [Related]

  • 40. Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease.
    Takahashi K, Tashiro H, Tajiri R, Takamori A, Uchida M, Kato G, Kurihara Y, Sadamatsu H, Kinoshita T, Yoshida M, Kawaguchi A, Kimura S, Sueoka-Aragane N, Kawayama T, Saga-naïve COPD Physical Activity Evaluation (SCOPE) Study Investigator Group.
    Int J Chron Obstruct Pulmon Dis; 2021 Nov 17; 16():3297-3307. PubMed ID: 34908832
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.